Use of GM-CSF as prophylaxis of ganciclovir-induced-severe bone marrow suppression [Prevención de mielotoxicidad en un caso de trasplante medular con factor estimulante de colonias granulocito-macrófago asociado a ganciclovir]
Por:
Reynoso Gómez E., Dueñas González A., Miranda López E., Sobrevilla Calvo P., Donis Hernández J., Texcocano Becerra J., Salinas Rojas V.
Publicada:
1 ene 1996
Resumen:
We report the first experience of the use of GM-CSF as prophylaxis of ganciclovir induced severe bone marrow suppression in a CMV seropositive patient with acute myeloid leukemia who underwent a complete remission after an allogeneic bone marrow transplantation from an identical HLA sibling who also was CMV seropositive. A succesful bone marrow engraftment was documented by day 14. Once peripheral blood counts stabilized, the patient received ganciclovir 5 mg/kg TIW. By day 73 severe neutropenia was documented but a spontaneous improvement ocurred with discontinuation of ganciclovir. From day 100 to day 110 he received daily ganciclovir at a dose of 5 mg/kg and the same dose of GM-CSF without signs of toxicity. There was no evidence of either acute graft versus host disease or of CMV infection. One year after transplantation he relapsed and died of complications of acute leukemia.
Filiaciones:
Reynoso Gómez E.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
Av. San Fernando, No. 22, Tlalpan, 14000, México, D.F., Mexico
Dueñas González A.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
Miranda López E.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
Sobrevilla Calvo P.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
Donis Hernández J.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
Texcocano Becerra J.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
Salinas Rojas V.:
Depto. de Hematología, Inst. Nac. de Cancerología, México, D.F., Mexico
|